1190853-96-3Relevant academic research and scientific papers
Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline γ-secretase inhibitors
Truong, Anh P.,Aubele, Danielle L.,Probst, Gary D.,Neitzel, Martin L.,Semko, Chris M.,Bowers, Simeon,Dressen, Darren,Hom, Roy K.,Konradi, Andrei W.,Sham, Hing L.,Garofalo, Albert W.,Keim, Pamela S.,Wu, Jing,Dappen, Michael S.,Wong, Karina,Goldbach, Erich,Quinn, Kevin P.,Sauer, John-Michael,Brigham, Elizabeth F.,Wallace, William,Nguyen, Lan,Hemphill, Susanna S.,Bova, Michael P.,Basi, Guriqbal
scheme or table, p. 4920 - 4923 (2009/12/26)
In this Letter, we report our strategy to design potent and metabolically stable γ-secretase inhibitors that are efficacious in reducing the cortical Aβx-40 levels in FVB mice via a single PO dose.
Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase
-
Page/Page column 89; 90, (2008/06/13)
The invention provides compounds of formula I: or pharmaceutically salts thereof where R1, R2, and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the desired compounds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of formula I.
